'''Ciglitazone''' ([[International Nonproprietary Name|INN]]) is a [[thiazolidinedione]]. Developed by [[Takeda Pharmaceuticals]] in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class.<ref>{{cite journal |vauthors=Pershadsingh HA, Szollosi J, Benson S, Hyun WC, Feuerstein BG, Kurtz TW |title=Effects of ciglitazone on blood pressure and intracellular calcium metabolism |journal=Hypertension |volume=21 |issue=6 Pt 2 |pages=1020–3 |date=June 1993 |pmid=8505086 |doi= 10.1161/01.hyp.21.6.1020|url=}}</ref><ref name=Hulin/><ref>{{cite journal |vauthors=Imoto H, Imamiya E, Momose Y, Sugiyama Y, Kimura H, Sohda T |title=Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives |journal=Chem. Pharm. Bull. |volume=50 |issue=10 |pages=1349–57 |date=October 2002 |pmid=12372861 |doi=10.1248/cpb.50.1349}}</ref><ref>{{cite journal |vauthors=Sohda T, Kawamatsu Y, Fujita T, Meguro K, Ikeda H |title=[Discovery and development of a new insulin sensitizing agent, pioglitazone] |language=Japanese |journal=Yakugaku Zasshi |volume=122 |issue=11 |pages=909–18 |date=November 2002 |pmid=12440149 |doi= 10.1248/yakushi.122.909|url=http://www.jstage.jst.go.jp/article/yakushi/122/11/909/_pdf}}</ref>

 
Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several [[analog (chemistry)|analogues]] were later developed, some of which—such as [[pioglitazone]] and [[troglitazone]]—made it to the market.<ref name=Hulin>{{cite journal |vauthors=Hulin B, McCarthy PA, Gibbs EM |title=The glitazone family of antidiabetic agents |journal=Current Pharmaceutical Design |volume=2 |pages=85–102 |year=1996 |url=https://books.google.com/books?id=IYn4Va7wtAoC&pg=PA86&dq=ciglitazone}}</ref>
